Calidi Biotherapeutics (CLDI) Non-Current Assets (2021 - 2026)

Calidi Biotherapeutics has reported Non-Current Assets for 6 years, with the latest figure at $1.8 million in Q2 2026.

• On a quarterly basis, Non-Current Assets fell 46.21% year-over-year to $1.8 million in Q2 2026; TTM through Jun 2026 was $10.7 million, a 30.05% decrease from a year earlier, with the FY2025 full-year figure at $2.6 million, down 34.24% from the prior year.
• Non-Current Assets was $1.8 million for Q2 2026 at Calidi Biotherapeutics, down from $2.6 million in the prior quarter.
• The five-year high for Non-Current Assets was $230.3 million in Q2 2022, with the low at -$1.6 million in Q2 2024.
• Average Non-Current Assets over 5 years is $39.4 million, with a median of $5.5 million recorded in 2024.
• The sharpest annual moves came in 2024 and 2025: Non-Current Assets sank 103.71% in 2024, then surged 305.73% in 2025.
• Over 5 years, Non-Current Assets stood at $42.5 million in 2022, then sank by 86.54% to $5.7 million in 2023, then sank by 30.81% to $4.0 million in 2024, then plunged by 34.24% to $2.6 million in 2025, then tumbled by 31.72% to $1.8 million in 2026.
• The last three Non-Current Assets figures came in at $1.8 million (Q2 2026), $2.6 million (Q4 2025), and $3.0 million (Q3 2025), per Business Quant data.